Page 104 - Micron News Today

A recent Nature Signal Transduction and Targeted Therapy journal study demonstrated the potential antiviral activity of a new Mpro inhibitor (SY110) against SARS-CoV-2 Omicron and its sublineages.

The study, currently available on the medRxiv* preprint server, indicates that omicron subvariant XBB/XBB.1.5 is more sensitive to vaccine-induced immunity than other co-circulating SARS-CoV-2 variants.

PCIe Gen 5 SSD speeds are set to offer a massive increase over PCIe Gen 4, and this is the year we're going to an impressive new SSD from Crucial.

Cayuga County Legislature Chairman David Gould calls it perfect timing.

The magnitude and quality of a key immune cell's response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found.

Cayuga County Legislature Chairman David Gould calls it perfect timing.

Researchers assess key attributes of rapid SARS-CoV-2 testing that would enable self-testing by individuals in the comfort of their homes.

In a recent study posted in the medRxiv* preprint server, scientists assessed the efficacy of sotrovimab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) treatment.

Scientists from the Republic of Korea have analyzed B-cell receptor repertoires induced by an mRNA-based coronavirus disease 2019 (COVID-19) vaccine and found that somatic hypermutations in B-cell receptor heavy chain are responsible for broadening its specificity for unexposed antigens.

Researchers provide evidence that a novel vaccine candidate robustly neutralized SARS-CoV-2 Omicron subvariants BQ.1.1 and XBB.